Top entities: Datar Cancer Genetics, United States — Food and Drug Administration, Vineet Datta, Darshana Patil, Dadasaheb Akolkar.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 14, 2026. Coverage continues to evolve.

Regulatory regulatory approval

Datar Cancer Genetics US FDA Clearance

Q: When did this event occur?

First reported May 14, 2026; last updated May 14, 2026.

Q: What is the market impact?

Direct. The US FDA clearance for Datar Cancer Genetics' CellDx-Tissue assay is expected to positively impact the company's market position and enable broader engagement with clinical and biopharmaceutical partners.

Analysis based on 10 articles · First reported May 14, 2026 · Last updated May 14, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The US FDA clearance for Datar Cancer Genetics' CellDx-Tissue assay is expected to positively impact the company's market position and enable broader engagement with clinical and biopharmaceutical partners. This regulatory endorsement validates the technology, potentially increasing investor confidence in the precision oncology sector.

Biotechnology Healthcare

Event Summary

Datar Cancer Genetics announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has been cleared by the United States — Food and Drug Administration. This clearance strengthens Datar Cancer Genetics' position in delivering a breakthrough platform for oncologists globally to make personalized clinical management decisions. The CellDx-Tissue assay uses targeted Next-Generation Sequencing of DNA and RNA from tumor tissue, analyzing 517 cancer-associated genes. This regulatory approval is a significant validation of Datar Cancer Genetics' science and quality systems, enabling the company to support oncologists with robust, standardized genomic information.

Key Actions

100 United States — Food and Drug Administration granted clearance Datar Cancer Genetics

Entities Involved

priv

Datar Cancer Genetics

Datar Cancer Genetics received US FDA clearance for its CellDx-Tissue assay, strengthening its position in precision oncology and enabling broader market engagement.

Importance 100 Sentiment 80

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration granted clearance for Datar Cancer Genetics' CellDx-Tissue assay, validating its scientific rigor and quality systems.

Importance 90 Sentiment 0

per

Vineet Datta

Vineet Datta, Senior Director at Datar Cancer Genetics, commented on the significance of the US FDA clearance for CellDx-Tissue.

Importance 30 Sentiment 0

per

Darshana Patil

Darshana Patil, Senior Director at Datar Cancer Genetics, highlighted the validation of science and quality systems through the US FDA clearance.

Importance 30 Sentiment 0

per

Dadasaheb Akolkar

Dadasaheb Akolkar, Director at Datar Cancer Genetics, emphasized the consistency and clinical orientation in the development of the CellDx-Tissue platform.

Importance 30 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard